Prelude Therapeutics

Gerald S. Falchook, Jon Glass, Varun Monga, Pierre Giglio, David Mauro, John Viscusi. Peggy Scherle, Neha Bhagwat, William Sun, Rachel Chiaverelli, Eric Mintah, Lydia Clements, Tanner M. Johanns, Meredith McKean. AACR-NCI-EORTC Annual Meeting 2021; October 7-10, 2021.

Varun Monga, Tanner Michael Johanns, Roger Stupp, Sunandana Chandra, Gerald Steven Falchook, Pierre Giglio, Alexander Philipovskiy, Iyad Alnahhas, Naveen Babbar, William Sun, Meredith McKean

Gerald S. Falchook, Manish R. Patel, Meredith McKean, Alexander Philipovskiy, Neha Bhagwat, Rachel Chiaverelli, William Sun, Michael Fossler, William Novotny, Michael Kurman, Sarah Rowe, Deborah Hunter, Mohammed Milhem

Lin H, Wang M, Zhang YW, Tong S, Leal RA, Shetty R, Vaddi K and Luengo JI. ACS Med. Chem. Lett. 2019, 10: 1033-1038. DOI: 10.1021/acsmedchemlett.9b00074

Lin H and Luengo JI. Bioorg. Med Chem Lett. 2019, 29: 1264-1269. DOI: 10.1016/j.bmcl.2019.03.042

David P. Bonita, M.D., has been on Prelude’s board since 2016. He has worked at OrbiMed Advisors since 2014 and serves on multiple public and private company boards.

Kris Vaddi, Ph.D., founded Prelude Therapeutics in 2016 and has served as its CEO and board member since then. Before Prelude, he led Orsenix from 2014 to 2016 and held roles at Incyte Corporation.

Madhu Pudipeddi, Ph.D., leads technical operations at Prelude Therapeutics. He previously worked at Novartis Pharmaceuticals for over 16 years in drug development and technical operations.

Martin Babler is CEO, Chairman, and President of Alumis, Inc. He previously led Principia Biopharma and Talima Therapeutics before their acquisitions.

Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines. Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline features highly selective KAT6A degraders and […]

175 Innovation BlvdWilmington, DE 19805Tel: (302) 467-1280 General Email: info@preludetx.com Investors & Media: rdoody@preludetx.com Medical Affairs: medinfo@preludetx.com

Prelude Therapeutics develops precision oncology medicines, including KAT6A degraders and JAK2V617F inhibitors, targeting clinically validated cancer pathways.

Prelude Therapeutics outlines its privacy practices for users of its website, governing data collection and user rights.